Mouwasat Medical Services Company (4002.SR)
- Previous Close
135.00 - Open
134.20 - Bid 132.00 x --
- Ask 132.40 x --
- Day's Range
131.40 - 135.20 - 52 Week Range
92.50 - 144.00 - Volume
29,455 - Avg. Volume
399,034 - Market Cap (intraday)
26.4B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
40.12 - EPS (TTM)
3.29 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield 1.50 (1.11%)
- Ex-Dividend Date May 8, 2023
- 1y Target Est
131.10
Mouwasat Medical Services Company acquires, manages, operates, and maintains hospitals, medical centers, drug stores, medicine warehouses, and pharmacies in the Kingdom of Saudi Arabia. It operates a network of hospitals in Dammam, Jubail, Madinah, Khobar, Qatif, and Riyadh that provides medical services. The company also operates skin care centers, which offer laser, cosmetic dermatological, reconstructive surgery, plastic surgery, weight loss, and other medical cosmetic services; a fertility unit; eye center; and a bariatric surgery clinic, as well as long term care that enhances functional recovery. In addition, it offers the stroke unit to diagnose and treat stroke; a cardiology center for diagnosing and treating cardiac diseases; nuclear medicine; and a unit that takes care for patients suffering from diabetes and diabetic foot, as well as rehabilitation devices and services. Further, the company involved in wholesale of medical equipment and drugs. Mouwasat Medical Services Company was founded in 1974 and is based in Dammam, the Kingdom of Saudi Arabia.
www.mouwasat.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: 4002.SR
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4002.SR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4002.SR
Valuation Measures
Market Cap
27.00B
Enterprise Value
27.64B
Trailing P/E
41.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.98
Price/Book (mrq)
8.24
Enterprise Value/Revenue
10.22
Enterprise Value/EBITDA
27.72
Financial Highlights
Profitability and Income Statement
Profit Margin
24.31%
Return on Assets (ttm)
9.82%
Return on Equity (ttm)
21.17%
Revenue (ttm)
2.71B
Net Income Avi to Common (ttm)
657.69M
Diluted EPS (ttm)
3.29
Balance Sheet and Cash Flow
Total Cash (mrq)
149.05M
Total Debt/Equity (mrq)
23.01%
Levered Free Cash Flow (ttm)
263.77M
Research Analysis: 4002.SR
Company Insights: 4002.SR
4002.SR does not have Company Insights